HURA: tuhurabio.com Company Value to Net Income

TuHURA Biosciences - graphic logo of issuer HURA

TuHURA Biosciences, Inc. (HURA) develops biopharmaceutical vaccines, where colossal testing costs are replaced by hyper-profitable scalability following patent approvals. Business efficiency relies on a streamlined, delay-free express delivery system for biomaterials. This chart reflects the current market value on GURU.Markets at -2.90, although geopolitical instability and sanctions could slow international research and disrupt raw material supplies.

Price to Earnings Ratio: TuHURA (HURA) for 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for TuHURA Biosciences Inc. (HURA)

General company analysis:TuHURA, HURA
Flagship merchandise of TuHURA Biosciences

For TuHURA Biosciences, Inc. (HURA), which specializes in AI-driven vaccines, the company's forward P/E reflects market expectations for future earnings against a backdrop of high development risks. This ratio correlates the current share price with the projected earnings per common share. Investors assess the investment payback period to determine the extent of the premium paid for the platform's technological potential. Monitoring this metric enables timely portfolio rebalancing, minimizing losses in the event of asset overvaluation.

Competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV